Table 1 –
Belgium | Finland | Italy | The Netherlands | Spain | Sweden | Switzerland | Total (excl. France) | France, Herault | France, Tarn | Total | |
---|---|---|---|---|---|---|---|---|---|---|---|
Age at randomisation, (yr), median (IQR) | 63 (60.2, 66.2) | 59 (54.8, 62.7) | 62 (58.4, 65.9) | 62 (58.0, 65.6) | 60 (57.4, 64.2) | 60 (57.2, 62.4) | 61 (57.8, 65.1) | 60 (57.1, 64.2) | 62 (58.8, 65.9) | 62 (57.9, 66.1) | 61 (57.9, 65.0) |
Randomised (n) | 8562 | 80 379 | 14 515 | 34 833 | 2197 | 11 852 | 9903 | 162 241 | 57 643 | 21 350 | 241 234 |
Screening, n (%) | 4307 (50%) | 31 970 (40%) | 7265 (50%) | 17 443 (50%) | 1056 (48%) | 5901 (50%) | 4948 (50%) | 72 890 (45%) | 28 784 (50%) | 10 879 (51%) | 112 553 (47%) |
Control, n (%) | 4255 (50%) | 48 409 (60%) | 7250 (50%) | 17 390 (50%) | 1141 (52%) | 5951 (50%) | 4955 (50%) | 89 351 (55%) | 28 859 (50%) | 10 471 (49%) | 128 681 (53%) |
Follow-up (yr), median (IQR) | 16 (11.1, 16.0) | 16 (13.8, 16.0) | 15 (13.2, 16.0) | 16 (13.8, 16.0) | 16 (15.1, 15.9) | 16 (13.9, 16.0) | 13 (11.6, 14.2) | 16 (13.0, 16.0) | 9 (8.9, 9.6) | 11 (9.8, 10.5) | 13 (9.5, 16.0) |
Screened at least once, n (%) | 3908 (91%) | 23 771 (74%) | 5730 (79%) | 16 502 (95%) | 1056 (100%) | 4484 (76%) | 4810 (97%) | 60 261 (83%) | 8121 (28%) | 4143 (38%) | 72 525 (64%) |
Screening tests done (n) | 6446 | 52 142 | 12 731 | 40 358 | 1846 | 15 475 | 12 068 | 141 066 | 10 060 | 5358 | 156 484 |
Screening rounds per man (mean) | 1.5 | 1.6 | 1.8 | 2.3 | 1.7 | 2.6 | 2.4 | 1.9 | 0.3 | 0.5 | 1.4 |
Positive tests (n) | 1058 | 5925 | 1443 | 9552 | 354 | 2896 | 2599 | 23 827 | 1627 | 821 | 26 275 |
Men with positive tests, n (%) | 914 (21%) | 4635 (14%) | 1054 (15%) | 6793 (39%) | 326 (31%) | 1537 (26%) | 1729 (35%) | 16 988 (23%) | 1560 (5%) | 760 (7%) | 19 308 (17%) |
Biopsies (n) | 752 | 5404 | 902 | 8541 | 263 | 2509 | 2027 | 20 398 | 468 | 418 | 21 284 |
Biopsies/positive tests (%) | 71.1 | 91.2 | 62.5 | 89.4 | 74.3 | 86.6 | 78.0 | 85.6 | 28.8 | 50.9 | 81.0 |
Men with biopsy at least once, n (%) | 684 (75%) | 4336 (94%) | 741 (70%) | 6187 (91%) | 244 (75%) | 1430 (93%) | 1494 (86%) | 15 116 (89%) | 468 (30%) | 410 (54%) | 15 994 (83%) |
Prostate cancer cases, screening group | |||||||||||
Prostate cancer cases overall in screening group, total (n) | 482 | 3500 | 560 | 2376 | 92 | 814 | 620 | 8444 | 1718 | 747 | 10 909 |
Screen-detected cancers (n) | 188 | 1632 | 197 | 1868 | 60 | 576 | 436 | 4957 | 229 | 128 | 5314 |
Interval cancers and cancers among nonattendees (n) | 294 | 1868 | 363 | 508 | 32 | 238 | 184 | 3487 | 1489 | 619 | 5595 |
Screen-detected cancers/biopsy (%) | 25.0 | 30.2 | 21.8 | 21.9 | 22.8 | 23.0 | 21.5 | 24.3 | 48.9 | 30.6 | 25.0 |
Cumulative incidence in screening group (%) a | 11.2 | 11.0 | 8.0 | 13.6 | 8.7 | 13.8 | 12.6 | 11.7 | 6.0 | 6.9 | 9.8 |
Prostate cancer cases, control group | |||||||||||
Prostate cancer cases overall in control cohort, total (n) | 393 | 4546 | 452 | 1325 | 60 | 592 | 364 | 7732 | 1541 | 690 | 9963 |
Cumulative incidence in control group (%) a | 9.2 | 9.4 | 6.5 | 7.6 | 5.3 | 9.9 | 7.4 | 8.7 | 5.4 | 6.6 | 7.8 |
IQR = interquartile range; PCa = prostate cancer.
Calculated as total cases/randomised, excluding patients with PCa before randomisation.